EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Microba Life Sciences's enterprise value is A$55.43 Mil.
Microba Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-10.28 Mil. Therefore, Microba Life Sciences's EV-to-EBITDA for today is -5.39.
The historical rank and industry rank for Microba Life Sciences's EV-to-EBITDA or its related term are showing as below:
ASX:MAP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.32 Med: -3.35 Max: -0.2
Current: -5.39
During the past 3 years, the highest EV-to-EBITDA of Microba Life Sciences was -0.20. The lowest was -8.32. And the median was -3.35.
ASX:MAP's EV-to-EBITDA is ranked worse than 100% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.39
vs ASX:MAP: -5.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Microba Life Sciences EV-to-EBITDA Historical Data
The historical data trend for Microba Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Microba Life Sciences's EV-to-EBITDA
For the Diagnostics & Research subindustry, Microba Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's EV-to-EBITDA falls into.
Microba Life Sciences's current Enterprise Value is A$55.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was A$-10.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (ASX:MAP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Microba Life Sciences's PE Ratio (TTM) for today is calculated as:
Microba Life Sciences's share price for today is A$0.155.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.031.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Microba Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:MAP has been successfully added to your